Phase II and III clinical trials have since been conducted and data from these studies indicate that mTOR inhibitors may be effective in the treatment of a variety of TSC manifestations, including SEGAs, LAM and AML [12, 55-57, 59, 69]. This evidence concerns the gene MTOR and lymphangioleiomyomatosis.